This educational resource was sponsored by Johnson & Johnson. In this educational resource, experts from a pharmacy and hospital provide an overview of their respective long-acting injectable ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has unveiled new data at the 2025 Psych Congress Elevate, highlighting significant advances in schizophrenia treatment. Real-world studies show that ...

Teva Pharmaceutical Industries Limited TEVA announced that the European Medicines Agency (“EMA”) has accepted its marketing ...

Medincell: The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable for the Treatment of Schizophrenia in Adults The olanzapine ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Kane: In talking ...

PARSIPPANY, N.J., and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the ...

The marketing application for TEV-‘749 is based on results from the Phase 3 SOLARIS trial, which demonstrated an efficacy and safety profile consistent with currently available olanzapine formulations ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Antipsychotic therapy substantially improves the ...

The olanzapine long-acting injectable (TEV-’749) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation1 administered every four weeks. If approved, TEV-‘749 could help fill a ...

The olanzapine long-acting injectable (TEV-’749) is designed to deliver the efficacy of olanzapine in a subcutaneous ...